期刊文献+

氟尿嘧啶治疗妊娠滋养细胞肿瘤的临床研究

Clinical research on the therapeutic effect of fluorouracil on gestational trophoblastic tumor
下载PDF
导出
摘要 目的:探讨氟尿嘧啶治疗妊娠滋养细胞肿瘤的最佳剂量范围。方法:选取2007年1月~2010年12月间我院收治的妊娠滋养细胞肿瘤患者的临床资料,通过分析疗效与不良反应的相关性,得出最佳给药剂量范围。结果:经过分析,氟尿嘧啶按体表面积给药剂量与化疗的副反应呈显著性相关;各剂量分组在骨髓抑制、恶心呕吐、腹泻、口腔溃疡等不良反应的比较中差异有统计学意义(P<0.05),而对于肝功能SGPT的升高以及疗效的比较中,差异无统计学意义(P>0.05)。结论:随着氟尿嘧啶给药剂量的增加,副反应也增加,而疗效却无显著性差异,因此氟尿嘧啶的给药剂量范围不应大于600-800mg/(m2·d)。 Objective:To investigate the optimal dose of fluorouracil in the chemotherapy of gestational trophoblastic neoplasia. Method:The clinical data of 141 patients diagnosed GTN from Jan 2007 to Dec 2010 in our hospital was studied. The associativity between therapeutic effect and adverse reaction of fluorouracil was analyzed. Results : There was a statistically significant correlation between the fluomuraeil dose and side effect of chemotherapy ( P 〈 0. 05 ). The adverse reactions between different fluorouracil doses were statistically different on the mye]osuppression, nausea and vomiting, diarrhea and oral ulcer ( P 〈 0. 05 ). These was no significant differences on the liver SGPT and efficacy ( P 〉 0.05 ). Conclusion: With the fluorouracil dose increasing, the adverse reaction of tluorouxacil is also increased hut the therapeutic effect is no changed. The dose of fluorouraeil should not exceed 600 - 800mg/( ^m2· d).
出处 《医学信息(中旬刊)》 2011年第7期3239-3240,共2页 Medical Information Operations Sciences Fascicule
关键词 氟尿嘧啶 妊娠滋养细胞肿瘤 副反应 Fluorouraeil Gestational trophoblastie neoplasia Adverse reaction
  • 相关文献

参考文献4

二级参考文献12

  • 1董桂娜,董英.恶性滋养细胞肿瘤保留生育机能145例分析[J].实用妇科与产科杂志,1993,9(2):93-95. 被引量:1
  • 2杨秀玉.恶性滋养细胞肿瘤晚期及耐药病例的诊治[J].实用医院临床杂志,2005,2(2):5-8. 被引量:6
  • 3杨隽钧,向阳,万希润,杨秀玉.恶性滋养细胞肿瘤的疗效和预后因素分析[J].现代妇产科进展,2006,15(11):816-821. 被引量:5
  • 4Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy [J] .J Reprod Med,2006,51 (10) :767 - 772. 被引量:1
  • 5Moodley M, Tunkyi K, Moodley J. Gestational trophoblastic syndrome: an audit of 112 patients at south African experience [J] .Int J Gynecnl Cancer, 2003,13(2) :234 - 239. 被引量:1
  • 6Szigetvari I, Szepesi J, Vegh G, et al.25 years' experience in the treat- ment of gestational trophoblastic neoplasia in Hungary [J]. J Reprod Med,.2006, 51 (10) :841 - 848. 被引量:1
  • 7Kohom El, Goldstein DP, Hancock BW, et al. Combining the staging system of the international federation of gynecdogy and abstetries with the scoring system of the world health organization for trophoblastic neoplasia. report of the working committee of the international society for the study of trophoblastic disease and the international gynecologic cancer society [j]. Int J Gynecol Cancer,2000, 10(1): 84-88. 被引量:1
  • 8Kohom EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment [J]. Int J Gynecol Cancer, 2001,11 ( 1 ) :73 - 77. 被引量:1
  • 9国家药典委员会编.中华人民共和国药典.临床用药须知-化学药和生物制品卷[M].北京:人民卫生出版社,2005:659-660. 被引量:1
  • 10VanIazrJ, RustumYM, AcklandSP, et al. Comparison of 5-Fluoro-2'-Deoxyurine with 5-fluorouracil and their role in the treatment of coloreetal[J] .Eur J Cancer, 1998,34:296-29. 被引量:1

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部